Heterogeneity of Dystrophin Expression in Patients with Duchenne and Becker Muscular Dystrophy

Overview

Journal Acta Neuropathol

Specialty Neurology

Date 1990 Jan 1

PMID 2205076

Citations 44

Authors

L V Nicholson

M A Johnson

D Gardner-Medwin

S Bhattacharya

J B Harris

Affiliations

Soon will be listed here.

Abstract

This report documents the results of an integrated biochemical and immunocytochemical investigation into the expression of dystrophin (the protein product of the Duchenne muscular dystrophy gene) in muscle biopsies from 226 patients. It is the first study in which dystrophin has been analysed on blots and on tissue sections in such a large number of patients using the same (monoclonal) antibody. The 140 patients with Xp21 muscular dystrophy who were included in this study represent a continuous spectrum of disease severity and this range was reflected in the heterogeneity of dystrophin expression which was observed with respect to abundance, size and the pattern of tissue localisation. Approximately 40% of biopsies obtained from patients diagnosed as having Duchenne muscular dystrophy (DMD) contained isolated clearly positive fibres and a further 20% had very weak labelling on a large number of fibres. Biopsies from patients with Becker muscular dystrophy (BMD) showed labelling patterns which varied from weak labelling on the majority of fibres to clear labelling on all fibres. Typically, however, there was inter- and intra-fibre variation in labelling intensity. Approximately 85% of the 52 BMD and 54 DMD patients who had unequivocal labelling on blots demonstrated a protein of abnormal size. The remaining 15% had a protein of normal size but reduced abundance. Overall, the estimated abundance of dystrophin correlated well with clinical assessments of the disease severity expressed in patients. We conclude that dystrophin analysis is an essential and dependable technique for the differential diagnosis of patients with Xp21 muscular dystrophy.

Citing Articles

Validation of a Muscle-Specific Tissue Image Analysis Tool for Quantitative Assessment of Dystrophin Staining in Frozen Muscle Biopsies.

Aeffner F, Faelan C, Moore S, Moody A, Black J, Charleston J Arch Pathol Lab Med. 2018; 143(2):197-205.

PMID: 30168727 PMC: 6813837. DOI: 10.5858/arpa.2017-0536-OA.

Proceedings of the 2017 National Toxicology Program Satellite Symposium.

Elmore S, Aeffner F, Bangari D, Crabbs T, Fossey S, Gad S Toxicol Pathol. 2017; 45(7):799-833.

PMID: 29113559 PMC: 5743204. DOI: 10.1177/0192623317733924.

Duchenne and Becker Muscular Dystrophies: A Review of Animal Models, Clinical End Points, and Biomarker Quantification.

Wilson K, Faelan C, Patterson-Kane J, Rudmann D, Moore S, Frank D Toxicol Pathol. 2017; 45(7):961-976.

PMID: 28974147 PMC: 5788182. DOI: 10.1177/0192623317734823.

Duchenne Muscular Dystrophy and Becker Muscular Dystrophy Confirmed by Multiplex Ligation-Dependent Probe Amplification: Genotype-Phenotype Correlation in a Large Cohort.

Vengalil S, Preethish-Kumar V, Polavarapu K, Mahadevappa M, Sekar D, Purushottam M J Clin Neurol. 2017; 13(1):91-97.

PMID: 28079318 PMC: 5242159. DOI: 10.3988/jcn.2017.13.1.91.

Impaired regenerative capacity and lower revertant fibre expansion in dystrophin-deficient mdx muscles on DBA/2 background.

Rodrigues M, Echigoya Y, Maruyama R, Lim K, Fukada S, Yokota T Sci Rep. 2016; 6:38371.

PMID: 27924830 PMC: 5141435. DOI: 10.1038/srep38371.

References

Nicholson L, DAVISON K, Johnson M, Slater C, Young C, Bhattacharya S . Dystrophin in skeletal muscle. II. Immunoreactivity in patients with Xp21 muscular dystrophy. J Neurol Sci. 1989; 94(1-3):137-46. DOI: 10.1016/0022-510x(89)90224-4. View

Hoffman E, Kunkel L . Dystrophin abnormalities in Duchenne/Becker muscular dystrophy. Neuron. 1989; 2(1):1019-29. DOI: 10.1016/0896-6273(89)90226-2. View

Koenig M, Beggs A, Moyer M, Scherpf S, Heindrich K, Bettecken T . The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet. 1989; 45(4):498-506. PMC: 1683519. View

Nicholson L, DAVISON K, Falkous G, Harwood C, ODonnell E, Slater C . Dystrophin in skeletal muscle. I. Western blot analysis using a monoclonal antibody. J Neurol Sci. 1989; 94(1-3):125-36. DOI: 10.1016/0022-510x(89)90223-2. View

Watkins S, Hoffman E, Slayter H, Kunkel L . Immunoelectron microscopic localization of dystrophin in myofibres. Nature. 1988; 333(6176):863-6. DOI: 10.1038/333863a0. View

Bonilla E, Samitt C, Miranda A, Hays A, Salviati G, DiMauro S . Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell surface. Cell. 1988; 54(4):447-52. DOI: 10.1016/0092-8674(88)90065-7. View

Feener C, Koenig M, Kunkel L . Alternative splicing of human dystrophin mRNA generates isoforms at the carboxy terminus. Nature. 1989; 338(6215):509-11. DOI: 10.1038/338509a0. View

Koenig M, Hoffman E, Bertelson C, Monaco A, Feener C, Kunkel L . Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell. 1987; 50(3):509-17. DOI: 10.1016/0092-8674(87)90504-6. View

Arahata K, Ishiura S, Ishiguro T, Tsukahara T, Suhara Y, EGUCHI C . Immunostaining of skeletal and cardiac muscle surface membrane with antibody against Duchenne muscular dystrophy peptide. Nature. 1988; 333(6176):861-3. DOI: 10.1038/333861a0. View

10.

Monaco A, Bertelson C, Moser H, Kunkel L . An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics. 1988; 2(1):90-5. DOI: 10.1016/0888-7543(88)90113-9. View

11.

Hoffman E, Kunkel L, Angelini C, Clarke A, Johnson M, Harris J . Improved diagnosis of Becker muscular dystrophy by dystrophin testing. Neurology. 1989; 39(8):1011-7. DOI: 10.1212/wnl.39.8.1011. View

12.

Bonilla E, Schmidt B, Samitt C, Miranda A, Hays A, de Oliveira A . Normal and dystrophin-deficient muscle fibers in carriers of the gene for Duchenne muscular dystrophy. Am J Pathol. 1988; 133(3):440-5. PMC: 1880814. View

13.

Worton R, Thompson M . Genetics of Duchenne muscular dystrophy. Annu Rev Genet. 1988; 22:601-29. DOI: 10.1146/annurev.ge.22.120188.003125. View

14.

Arahata K, Hoffman E, Kunkel L, Ishiura S, Tsukahara T, Ishihara T . Dystrophin diagnosis: comparison of dystrophin abnormalities by immunofluorescence and immunoblot analyses. Proc Natl Acad Sci U S A. 1989; 86(18):7154-8. PMC: 298014. DOI: 10.1073/pnas.86.18.7154. View

15.

Koenig M, Monaco A, Kunkel L . The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell. 1988; 53(2):219-28. DOI: 10.1016/0092-8674(88)90383-2. View

16.

Hori S, Sugiura H, Shimizu T, Hirabayashi T, Ohtani S, Yoshida M . Detection of dystrophin on two-dimensional gel electrophoresis. Biochem Biophys Res Commun. 1989; 161(2):726-31. DOI: 10.1016/0006-291x(89)92660-0. View

17.

Bradley W, Jones M, Mussini J, Fawcett P . Becker-type muscular dystrophy. Muscle Nerve. 1978; 1(2):111-32. DOI: 10.1002/mus.880010204. View

18.

Patel K, Voit T, Dunn M, Strong P, Dubowitz V . Dystrophin and nebulin in the muscular dystrophies. J Neurol Sci. 1988; 87(2-3):315-26. DOI: 10.1016/0022-510x(88)90256-0. View

19.

den Dunnen J, Grootscholten P, Bakker E, Blonden L, Ginjaar H, Wapenaar M . Topography of the Duchenne muscular dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications. Am J Hum Genet. 1989; 45(6):835-47. PMC: 1683480. View

20.

BECKER P, KIENER F . [A new x-chromosomal muscular dystrophy]. Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr. 1955; 193(4):427-48. DOI: 10.1007/BF00343141. View